Metabolic therapy for heart disease: Impact of trimetazidine

Heart Failure Reviews

Volumn 10, Issue 4, 2005, Pages 281-288

  Sabbah, Hani N ^a,c   Stanley, William C ^b  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A ACYLTRANSFERASE; ACYL COENZYME A; ADENOSINE TRIPHOSPHATE; ANTIANGINA PECTORIS AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBOHYDRATE; CARNITINE PALMITOYLTRANSFERASE; CARNITINE PALMITOYLTRANSFERASE INHIBITOR; DILTIAZEM; ETOMOXIR; FATTY ACID; GLUCOSE; GLYCERYL TRINITRATE; INSULIN; ISOSORBIDE MONONITRATE; LACTIC ACID; METOPROLOL; NIFEDIPINE; NITRIC ACID DERIVATIVE; OXFENICINE; OXYGEN; PERHEXILINE; POTASSIUM; POTASSIUM CHANNEL STIMULATING AGENT; PROPRANOLOL; TRIMETAZIDINE; UNINDEXED DRUG; VERAPAMIL;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; CARBOHYDRATE METABOLISM; CARDIOMYOPATHY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG MECHANISM; FATTY ACID METABOLISM; HEART DISEASE; HEART FAILURE; HEART HEMODYNAMICS; HEART MUSCLE METABOLISM; HUMAN; LIPOLYSIS; LIVER TOXICITY; NEUROPATHY; NONHUMAN; OXYGEN CONSUMPTION; STABLE ANGINA PECTORIS;

CARNITINE O-PALMITOYLTRANSFERASE; FATTY ACIDS; HEART DISEASES; HUMANS; LIPOLYSIS; OXIDATION-REDUCTION; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 33645465083     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-005-7541-5     Document Type: Article

References (59)

1. Crea F, Gaspardone A. New look to an old symptom: Angina pectoris. Circulation 1997;96:3766-3773.
2. Li RA, Leppo M, Miki T, Seino S, Marbán E. Molecular Basis of Electrocardiographic ST-Segment Elevation. Circ Res 2001;87:837-839.
3. Packer M. Combined beta-adrenergic and calcium-entry blockade in angina patients. N Engl J Med 1989;320,709-718.
4. Akhras F, Jackson G. Efficacy of nifedipine and isosorbide mononitrate in combination with atenolol in stable angina. Lancet 1991;338:1036-1039.
5. Savonitto S, Ardissino D, Egstrup K, Rasmussen K, Bae AE, Omland T, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. J Am Coll Cardiol 1996;27:311-316.
6. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, on behalf of the TIBET Study Group. The total Ischemic Burden European Trial (TIBET). Eur Heart J 1996;17:96-103.
7. Thandani U. Management of patients with chronic stable angina low risk for serious cardiac events. Am J Cardiol 1997;79:24-30.
8. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochem Biophys Acta 1994;1213:263-276.
9. Wisneski JA, Gertz EW, Neese RA, Mayr M. Myocardial metabolism of free fatty acids. Studies with 14C-labeled substrates in humans. J Clin Invest 1987;79:359-366.
10. Wisneski JA, Gertz EW, Neese RA, Gruenke LD, Morris DL, Craig JC. Metabolic fate of extracted glucose in normal human myocardium. J Clin Invest 1985;76:1819-1827.
11. Gertz EW, Wisneski JA, Stanley WC, Neese RA. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments.
12. Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation 1997;95:313-315.
13. Budingen T. Uber die Moglichkeit einer Ernahrungsbehandlund des Herzmuskels durch Einbringer von Traubenzuckerlosungen in den groben Kreislauf. Dt. Arch. Klin. Med. 1914;114:534-579.
14. Sodi-Pollares D, Testelli MR, Fishleder BL, Bisteni A, Medrano GA, DeMicheli A. Effects of an intravenous infusion of a potassium-glucose-insulin solution on the electrocardiographic signs of myocardial infarction. Am J Cardiol 1962;9:166-181.
15. Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction. An overview of randomized placebo-controlled trials. Circulation 1997;96:1132-1136.
16. Diaz R, Paolasso EA, Piegas LS, et al. Metabolic modulation of acute myocardial infarction: The ECLA Glucose-Insulin-Potassium Pilot Trial. Circulation 1998;98:2227-2234.
17. Ceremuzynski L, Budaj A, Czepiel A, et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter pol-GIK trial. Cardiovas Drugs Ther 1999;13:191-200.
18. Stanley WC, Lopaschuk GD, Hall JL, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischemic conditions. Potential for pharmacological interventions. Cardiovas Res 1997;33:243-257.
19. Lopaschuk GD, Belke DD, Gamble J, Itoi T, Schonekess BO. Regulation of fatty acid oxidation in the mammalian heart in health and disease. Biochem Biophys Acta 1994;1213:263-276.
20. Lassers BW, Wahqvist ML, Kaijser L, Carlson LA. Effect of nicotinic acid on myocardial metabolism in man at rest and during exercise. J Appl Physiol 1972;33:72-80.
21. Rowe MJ, Dolder MA, Kirby BJ, Oliver MF. Effect of a nicotinic-acid analogue on raised plasma-free-fatty-acids after acute myocardial infarction. Lancet 1973;ii:814-818.
22. Rowe MJ, Neilson JMM, Oliver MF. Control of ventricular arrhythmias during myocardial infarction by antilipolytic treatment using a nicotinic-acid analogue. Lancet 1975;i:295-300.
23. Horgan JH, O'Callaghan WG, Teo KK. Therapy of angina pectoris with low-dose perhexiline. J Cardiovasc Pharmacol 1981;3:566-572.
24. Shah RR, Oates NS, Idle JR, Smith RL, Lockhart JDF. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy. BMJ 1982;284:295-299.
25. Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut 1984;25:1057-1064.
26. Lopaschuk GD, Wall SR, Olley PM, Davies NJ. Etomoxir, a carnitine palmitoyl transferase I inhibitor, protects hearts from fatty acid-induced ischemia injury independent of changes in long chain acylcarnitine. Circ Res 1988;63:1036-1043.
27. Drake-Holland AJ, Passingham JE. The effect of Oxfenicine on cardiac carbohydrate metabolism in intact dogs. Basic Res Cardiol 1983;78:19-27.
28. Higgins AJ, Morville M, Burges RA, Gardiner DG, Page MG, Blackburn KJ. Oxfenicine diverts rat muscle metabolism from fatty acid to carbohydrate oxidation and protects the ischemia rat heart. Life Sci 1980,27:963-970.
29. Pepine CJ, Wolff AA for the Ranolazine Study Group. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 1999;84:46-50.
30. Kantor PF, Lucien A, Korak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580-588.
31. Sellier P. Chronic effects of trimetazidine on ergometric parameters in effort angina. Cariovasc Drugs Ther 1990;4:822-823.
32. Sellier P, Harpy C, Corona P, Audouin P, Ourbak P. Acute effects of trimetazidine on ergometric parameters in effort angina. Cardiovasc Drugs Ther 1990;4:820-821.
33. Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A. Comparison of trimetazidine with nifedipine in effort angina: A double-blind, crossover study. Cardiovasc Drugs Ther 1990;4:853-860.
34. Detry JM, Sellier P, Pennaforte S, Cokkinos D, Dargie H, Mathes P. Trimetazidine: A new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994,37:279-288.
35. ManchandaSC, Krischnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997;78:353-357.
36. Stanley WC, Marzilli M. Metabolic therapy in the treatment of ischaemic heart disease: The pharmacology of trimetazidine. Fundamental and Clin Pharmacol 2003;17:133-145.
37. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M, Volterrani M, Rosano GMC. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814-1821.
38. Lopaschuk GD. Optimizing cardiac energy metabolism: How can fatty acid and carbohydrate metabolism be manipulated? Cor Art Dis 2000;12:S8-S11.
39. Bashore TM, Magorien DJ, Letterio J, Shaffer P, Unverferth DV. Histologic and biochemical correlates of left ventricular chamber dynamics in man. J Am Col Cardiol 1987;9:734-742.
40. Hoppel CL, Tandler B, Parland W, Turkaly JS, Albers LD. Hamster cardiomyopathy: A defect in oxidative phosphorylation in the cardiac interfibrillar mitochondria. J Biol Chem 1982;257:1540-1548.
41. Sabbah HN, Sharov VG, Riddle JM, Kono T, Lesch M, Goldstein S: Mitochondrial abnormalities in myocardium of dogs with chronic heart failure. J Mol. Cell Cardiol 1992;24:1333-1347.
42. Sharov VG, Sabbah HN, Cook JM, Silverman N, Lesch M, Goldstein S: Abnormal mitochondrial function in myocardium of dogs with chronic heart failure. J Mol Cell Cardiol 1998;30:1757-1762.
43. Stanley WC, CL Hoppel. Mitochondrial dysfunction in heart failure: potential for therapeutic interventions? Cardiovasc Res 2000;45:805-806.
44. Paolisso G,Gambardella A, Galzerano D, Amore AD', Rubino P, Verza M, Teasuro P, Varricchio M, Onofrio FD'. Total body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994;43:174-78.
45. Opie L. The heart: Physiology, from cell to circulation. Philadelphia: Lippincott-Raven, 1998.
46. Stanley WC, Lopaschuk GD, Hall JH, McCormack JG. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions: Potential for pharmacological interventions. Cardiovasc Res 1997;33:243-257.
47. Panchal AR, Stanley WC, Kerner J, Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 1998;4:121-126.
48. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA, Hatfield BA, Marcoux LG, Malloy CR. Effects of metoprolol on myocardial function and energetics in patients with ischemic dilated cardiomyopathy: A randomized double blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320.
49. Mjø OD: Effect of free fatty acids on myocardial function and oxygen consumption in intact dogs. J Clin Invest 1971;50:1386-1389.
50. Simonsen S. Kjekshus JK. The effect of free fatty acids on myocardial oxygen consumption during atrial pacing and catecholamine infusion in man. Circulation. 1978;58:484-491.
51. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol 2000,278:H1345-H1351.
52. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, Henderson GN, de-Marco T, Chatterjee K: Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 1994;23:1617-1624.
53. 2+ in hearts of cardiomyopathic hamsters. Am J Physiol 1993;264: H2188-H2197.
54. D'hahan N, Taouil K, Dassouli A, Morel JE: Long-term therapy with trimetazidine in cardiomyopathic Syrian hamster BIO 14:6. Euro J Pharmacol. 1997;328:163- 174.
55. Turcani M, H Rupp. Etomoxir improves left ventricular performance of pressure-overloaded rat heart. Circulation 1997;96:3681-3686.
56. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischemic cardiomyopathy. Eur Heart J 1990;11:207-212.
57. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy. Eur Heart J 2001;22:2164-2170.
58. Fragasso G, Piatti PM, Monti L, et al. Short and long-term effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003; 146:E18.
59. Rosano GMC, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ventricular function in diabetic patients with coronary disease: A double-blind placebo-controlled study. Cardiovasc Diabet 2003;2:16-25.